WESTFORD, Mass., July 22 Cynosure, Inc.(Nasdaq: CYNO), a leading developer and manufacturer of a broad array oflight-based aesthetic treatment systems, has received the European CE Mark forSmartlipo MPX(TM), the company's high-powered, dual-wavelength aestheticworkstation to liquefy fat and tighten skin through collagen remodeling. TheCE Mark certifies that the Smartlipo MPX conforms to the essential health andsafety requirements of the European Medical Device Directive.
Cynosure expects to launch Smartlipo MPX through its subsidiaries in theEuropean Union beginning this quarter. Cynosure has marketed and soldSmartlipo MPX in the United States since the second quarter of 2008.
"The quality associated with the Smartlipo brand is an importantdifferentiator for Cynosure among U.S. customers and consumers, and we expectthis to be equally true as we introduce Smartlipo MPX to the internationalmarket," said President and Chief Executive Officer Michael Davin. "Webelieve the integration of our MultiPlex(TM) technology and SmartSense(TM)intelligent delivery system makes Smartlipo MPX the ideal platform blendingbody sculpting and tissue tightening through coagulation. Together, theseapplications are forecast to help drive the global aesthetic market from $8.4billion in 2007 to more than $15 billion by 2011(1). We expect that ourcontinued focus on innovation will enable Cynosure to remain at the forefrontof this high-growth market."
"The EU represents the next phase of our multi-pronged strategy to expandthe geographic reach of our Smartlipo technology," Davin said. "Smartlipo MPXtraining for our European subsidiaries is already underway, and they are eagerto introduce the product in their markets. This rollout will be followed by atargeted launch in select countries in the Middle East, as well as ongoingsubmissions for regulatory approvals in the Asia Pacific region."
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that areused by physicians and other practitioners to perform non-invasive andminimally invasive procedures to remove hair, treat vascular lesions,rejuvenate skin through the treatment of shallow vascular and pigmentedlesions, laser lipolysis and temporarily reduce the appearance of cellulite.Cynosure's products include a broad range of laser and other light-basedenergy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, aswell as intense pulsed light. Cynosure was founded in 1991.
For corporate or product information, contact Cynosure at 800-886-2966, orvisit http://www.cynosure.com.
Any statements in this press release about future expectations, plans andprospects for Cynosure, Inc., including statements about the company'sexpectations regarding the performance and market acceptance of the SmartlipoMPX and future financial performance, as well as other statements containingthe words "believes," "anticipates," "plans," "expects," "will" and similarexpressions, constitute forward-looking statements within the meaning of ThePrivate Securities Litigation Reform Act of 1995. Actual results may differmaterially from those indicated by such forward-looking statements as a resultof various important factors, including market acceptance of the Smartlipo MPX,Cynosure's reliance on sole source suppliers, the inability to accuratelypredict the timing or outcome of regulatory decisions, changes in consumerpreferences, competition in the aesthetic laser industry, economic, market,technological and other factors discussed in Cynosure's most recent AnnualReport on Form 10-K and Quarterly Reports on Form 10-Q, each of which is filedwith the Securities and Exchange Commission. In addition, the forward-lookingstatements included in this press release represent Cynosure's views as of thedate of this press release. Cynosure anticipate